- Home
- GILT vs PRTC Comparison
GILT vs PRTC Comparison
Compare GILT & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GILT
- PRTC
- Stock Information
- Founded
- GILT 1987
- PRTC 2015
- Country
- GILT Israel
- PRTC United States
- Employees
- GILT N/A
- PRTC N/A
- Industry
- GILT Radio And Television Broadcasting And Communications Equipment
- PRTC Biotechnology: Pharmaceutical Preparations
- Sector
- GILT Technology
- PRTC Health Care
- Exchange
- GILT Nasdaq
- PRTC Nasdaq
- Market Cap
- GILT 381.2M
- PRTC 439.8M
- IPO Year
- GILT 1993
- PRTC N/A
- Fundamental
- Price
- GILT $6.43
- PRTC $17.90
- Analyst Decision
- GILT Strong Buy
- PRTC Buy
- Analyst Count
- GILT 2
- PRTC 1
- Target Price
- GILT $8.50
- PRTC $45.00
- AVG Volume (30 Days)
- GILT 457.7K
- PRTC 2.0K
- Earning Date
- GILT 08-06-2025
- PRTC 04-30-2025
- Dividend Yield
- GILT N/A
- PRTC N/A
- EPS Growth
- GILT N/A
- PRTC N/A
- EPS
- GILT 0.24
- PRTC 0.21
- Revenue
- GILT $321,407,000.00
- PRTC $4,828,000.00
- Revenue This Year
- GILT $42.88
- PRTC $35.98
- Revenue Next Year
- GILT $13.26
- PRTC $115.38
- P/E Ratio
- GILT $27.05
- PRTC $7.81
- Revenue Growth
- GILT 13.49
- PRTC 44.98
- 52 Week Low
- GILT $4.04
- PRTC $13.30
- 52 Week High
- GILT $8.05
- PRTC $28.39
- Technical
- Relative Strength Index (RSI)
- GILT 54.60
- PRTC 46.07
- Support Level
- GILT $6.24
- PRTC $19.00
- Resistance Level
- GILT $6.43
- PRTC $19.80
- Average True Range (ATR)
- GILT 0.20
- PRTC 0.33
- MACD
- GILT 0.05
- PRTC -0.12
- Stochastic Oscillator
- GILT 81.13
- PRTC 16.30
About GILT Gilat Satellite Networks Ltd.
Gilat Satellite Networks Ltd is a provider of satellite-based broadband communications. The company designs and manufactures ground-based satellite communications equipment and provides comprehensive solutions and end-to-end services. Its portfolio includes a cloud-based satellite network platform, very small aperture terminals (VSATs), amplifiers, high-speed modems, on-the-move antennas and high-power solid-state power amplifiers (SSPAs), block-up converters (BUCs), and Transceivers. The company's solutions support multiple applications with a full portfolio of products to address key applications including broadband access, cellular backhaul, enterprise, in-flight connectivity, maritime, trains, defense, and public safety.
About PRTC PureTech Health plc
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.